Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Differences in epidemiolo… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Differences in epidemiology of candidaemia in the Nordic countries - what is to blame?

Artikel i vetenskaplig tidskrift
Författare Liv Hesstvedt
Maiken C Arendrup
Eira Poikonen
Lena Klingpor
Vanda Friman
Ingvild Nordøy
Publicerad i Mycoses
Volym 60
Nummer/häfte 1
Sidor 11-19
ISSN 1439-0507
Publiceringsår 2017
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 11-19
Språk en
Länkar dx.doi.org/10.1111/myc.12535
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Anti-Bacterial Agents, administration & dosage, adverse effects, therapeutic use, Antifungal Agents, administration & dosage, adverse effects, therapeutic use, Candida glabrata, drug effects, isolation & purification, Candidemia, drug therapy, epidemiology, microbiology, Causality, Cross Infection, drug therapy, epidemiology, microbiology, Demography, Drug Resistance, Fungal, Female, Humans, Incidence, Male, Population Health, Practice Patterns, Physicians', statistics & numerical data, Risk Factors, Scandinavian and Nordic Countries, epidemiology, Statistics as Topic
Ämneskategorier Infektionsmedicin

Sammanfattning

National data from Denmark, Finland, Norway and Sweden demonstrate remarkable differences in candidaemia epidemiology. Only Denmark has reported a high incidence of 10 per 100 000 inhabitants and a species shift towards increased C. glabrata candidaemias. The reasons for this development remain unclear. The aim of this study was to explore possible contributing factors for the differences in Candida epidemiology in the Nordic countries. We used public data from 2011 from Denmark, Finland, Norway and Sweden on epidemiology, demographics, health facilities, predisposing risk factors, consumption of antimicrobial drugs and fungicides in agricultural industry. Only the prevalence of haematological malignancies (P < 0.001) was significantly higher in Denmark compared to the other Nordic countries. The antibacterial drug use of metronidazole, piperacillin-tazobactam, ciprofloxacin, colistin and carbapenems, and antifungal use of fluconazole in humans (P < 0.001), were significantly higher in Denmark compared to the other Nordic countries (all P < 0.001). Our findings suggest haematological malignancy, the use of certain antibacterial drugs and azoles in humans as possible contributing factors for the differences in Candida epidemiology. However, our results should be interpreted with caution due to the lack of long-term, case-specific data. Further studies are needed.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?